Planning · worksheet · CSVtoCSA editorial

Risk-to-evidence worksheet

Version 2.0 · Updated 2026-09-21 · Planning

Connect a credible failure to controls, evidence gaps and an assurance decision.

Adapt this template to your intended use, applicable requirements, and approved procedures.

When to use it

A risk rating exists but the testing rationale is unclear.

Information needed before starting

  • Defined intended use and important requirements
  • Credible failure scenarios and consequences
  • Existing controls and available evidence

Field instructions

  • Failure: Describe a credible incorrect, missing or delayed result and trace it to the affected process, record or decision. Distinguish severity from how often it could occur.
  • Cause/context: Describe the input, configuration or operating condition that makes the failure credible; distinguish a proposed cause from a confirmed one.
  • Consequence: Trace the failure to the affected product, process, record or decision and explain why that consequence matters.
  • Existing control: Describe the preventive or detective measure, responsible role and evidence that it works for the identified failure.
  • Control limitation: Explain which failure paths the control does not prevent or detect, and what evidence or restriction addresses that gap.
  • Existing evidence: Reference the exact evidence, version, date and assessed conditions. Explain the claim it supports, how it was reviewed and what remains unproven locally.
  • Gap: State exactly which claim is unsupported by the existing evidence and what information is missing.
  • New evidence: Specify the additional test, review or observation, its expected result and the evidence to retain.
  • Remaining uncertainty: Describe what the combined evidence still cannot establish and how the uncertainty limits the decision.
  • Owner/action: Assign the evidence or control action to an accountable role, with a due date and completion reference.

Does each assurance activity answer an identified question? Remove activities that add no useful evidence and address unexplained gaps.

Completed fictional example

Fictional teaching example; replace its values with your own assessed facts and evidence.

FieldCompleted example
FailureQuarantined material is accepted as released
Cause/contextIncorrect source-to-destination status mapping
ConsequenceMaterial may be issued to production incorrectly
Existing controlERP issue blocking based on accepted disposition
Control limitationBlocking depends on correct mapping
Existing evidenceReviewed standard ERP blocking behavior
GapLocal mapping and interface recovery
New evidenceMapping comparison, invalid-code challenge, delayed/duplicate message scenarios
Remaining uncertaintyNew status codes introduced later
Owner/actionInterface owner controls mapping changes and monitors unknown codes

Blank template

System / record ID: ____________________

Prepared by / date: ____________________

Required review / approval under local procedure: ____________________

FieldYour entry
Failure____________________
Cause/context____________________
Consequence____________________
Existing control____________________
Control limitation____________________
Existing evidence____________________
Gap____________________
New evidence____________________
Remaining uncertainty____________________
Owner/action____________________
Relevant regulations and guidance

These sources apply within their stated scope. The suggested worksheet fields, test designs and fictional decisions are practitioner recommendations, unless a source requirement is expressly identified. Completing a template does not establish compliance.

Computer Software Assurance for Production and Quality Management System Software ↗

Regulatory guidance / GMP guideline · United States · February 2026

Scope: Medical-device manufacturers assuring software used in production or their quality management system.

Relevance: For medical-device production or QMS software, supports selecting assurance activities from intended use, risk and available evidence. It is nonbinding guidance and does not determine other sectors’ obligations.

Status: Final / published · Checked 2026-09-21

Publication identity, scope and status checked against the linked official source. This is not an independent audit of every retained guide statement.

Read source details and applicability →

EudraLex Volume 4, Annex 11 — Computerised Systems ↗

Regulatory guidance / GMP guideline · European Union · January 2011 revision

Scope: Computerised systems supporting activities in the applicable EU pharmaceutical GMP context.

Relevance: For computerised systems used in EU GMP activities, informs lifecycle, supplier and record controls. Confirm applicability to the actual activity; the example does not establish it.

Status: Final / published · Checked 2026-09-21

The Commission index confirms the January 2011 operative revision. The linked PDF could not be retrieved in this check; retained detailed section mappings need review against an authorized copy.

Read source details and applicability →

21 CFR Part 11 — Electronic Records; Electronic Signatures ↗

Regulation · United States · Current eCFR text

Scope: Electronic records and signatures within FDA Part 11 scope, tied to the underlying required records.

Relevance: Assess applicability to electronic records required by FDA predicate rules and electronic signatures used in their place. The presence of an electronic record alone is not an applicability conclusion.

Status: Final / published · Checked 2026-09-21

Publication identity, scope and status checked against the linked official source. This is not an independent audit of every retained guide statement.

Read source details and applicability →
Was this useful? Leave feedback

Was this resource useful?

Was this template clear and useful? Tell us which instruction or field could be improved.

Loading contribution options…

Questions and moderated discussion

Questions and discussion

Ask a question or share a perspective. Contributions are reviewed before publication.

Loading contribution options…

Suggest a correction

Sent privately to the editorial moderation queue. Your account email and correction are not published as a comment. Do not include confidential or personal information.

Resource: Risk-to-evidence worksheet

Loading sign-in status…

Correction details